Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Jing Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9996-0815; OpenAlex author ID A5101567689. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. PLIN5 affects the fibrosis and progression of pancreatic cancer via modulation of pancreatic stellate cells. Co-author DOI 10.1016/j.lfs.2025.124060↗
  2. The glycolytic enzyme PGK1 phosphorylates MORC2 to Confer radioresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-025-08177-9↗
  3. Hexokinase 2 nonmetabolic function-mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1111/cas.16204↗
  4. Integrative Analysis of PAIP2B to Identify a Novel Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1055/s-0043-1777789↗
  5. Derivation and validation of a nomogram model for venous thromboembolism in patients undergoing borderline resectable pancreatic cancer surgery Co-author DOI 10.21203/rs.3.rs-2469113/v1↗
  6. A nomogram model to predict the portal vein thrombosis risk after surgery in patients with pancreatic cancer. Co-author DOI 10.3389/fsurg.2023.1293004↗
  7. Without compromising surgical outcomes, neoadjuvant therapy might be a better approach to improve the prognosis of patients with advanced pancreatic cancer. First author DOI 10.21037/gs-2021-06↗
  8. Prognostic Value of Preoperative NLR and Vascular Reconstructive Technology in Patients With Pancreatic Cancer of Portal System Invasion: A Real World Study. First author DOI 10.3389/fonc.2021.682928↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shaocheng Lyu · 4 shared papers, 2021–2023 · strength 0.77
  2. Ren Lang · 4 shared papers, 2021–2023 · strength 0.77
  3. Yingying Tong · 3 shared papers, 2023–2025 · strength 0.63
  4. yaoxian Xiang · 3 shared papers, 2023–2025 · strength 0.63
  5. Li Wang · 2 shared papers, 2024–2025 · strength 0.43
  6. Dong Yan · 2 shared papers, 2024–2025 · strength 0.43
  7. Songping Cui · 2 shared papers, 2023 · strength 0.41
  8. Qiang He · 2 shared papers, 2021–2023 · strength 0.33
  9. Xu Guo · 1 shared paper, 2025 · strength 0.27
  10. Bin Zhu · 1 shared paper, 2025 · strength 0.27
  11. Nengwei Zhang · 1 shared paper, 2025 · strength 0.27
  12. Jili Hu · 1 shared paper, 2025 · strength 0.27
  13. Zhuoyin Wang · 1 shared paper, 2025 · strength 0.27
  14. Lijun Yang · 1 shared paper, 2025 · strength 0.22
  15. Han-Xuan Wang · 1 shared paper, 2023 · strength 0.22
  16. Li Wang · 1 shared paper, 2023 · strength 0.19
  17. Yan Dong · 1 shared paper, 2023 · strength 0.19
  18. Xinxue Zhang · 1 shared paper, 2021 · strength 0.14
  19. Lin Zhou · 1 shared paper, 2021 · strength 0.14
  20. Li-chao Pan · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.